CDK4 and neoplasm: Finally, we screened a panel of 22 cancer cell lines for their response to different CDK4/6 inhibitors and we show that F9 loss-of-function confers a partial resistance to the proliferative arrest induced by CDK4/6 inhibitors in other tumour types.